Drugs / HRS-4642

Trials 17 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05533463 Sep 2022 → Jun 2024 overdue Jiangsu HengRui Medicine Co., Ltd. Active not recruiting No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT06955390 May → Dec 2025 overdue cancer Henan Cancer Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT06773130 Feb 2025 → Aug 2026 overdue pancreatic ductal adenocarcinoma West China Hospital Active not recruiting No outcome recorded
Phase 1/2 NCT06520488 Aug 2024 → Mar 2027 expected cancer Jiangsu HengRui Medicine Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06385678 Jul 2024 → Dec 2025 overdue Jiangsu HengRui Medicine Co., Ltd. Active not recruiting No outcome recorded
Phase 1/2 NCT06427239 Jun 2024 → Jun 2027 expected malignant pancreatic neoplasm Fudan University Recruiting No outcome recorded
Phase 210 trials
Phase 2 NCT07691593 Jun 2026 → Oct 2027 expected malignant pancreatic neoplasm Changhai Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07503639 Apr 2026 → Apr 2028 expected colorectal cancer Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT07240766 Feb 2026 → May 2027 expected adenocarcinoma Zhejiang University Recruiting No outcome recorded
Phase 2 NCT07438106 Jan 2026 → Oct 2027 expected The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
Phase 2 NCT07131514 Aug 2025 → Jun 2027 expected malignant pancreatic neoplasm Ruijin Hospital Recruiting No outcome recorded
Phase 2 NCT06938282 May 2025 → Apr 2027 expected malignant pancreatic neoplasm Shanghai Zhongshan Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06770452 Mar 2025 → Feb 2027 expected carcinoma Zhejiang University Recruiting No outcome recorded
Phase 2 NCT06587061 Dec 2024 → Jun 2027 expected malignant pancreatic neoplasm Ruijin Hospital Recruiting No outcome recorded
Phase 2 NCT06620848 Nov 2024 → Dec 2026 expected biliary tract cancer Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase 2 NCT06547736 Oct 2024 → Mar 2027 expected malignant pancreatic neoplasm Fudan University Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07232875 Nov 2025 → Apr 2029 expected Jiangsu HengRui Medicine Co., Ltd. Recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07296341 Comparator Jan 2026 → Oct 2027 expected Shanghai Hengrui Pharmaceutical Co., Ltd. Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as HRS-4642 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385678
17

NCT06587061

NCT07296341

NCT06955390

NCT06938282

NCT05533463

NCT07438106

NCT07240766

NCT06520488

NCT07691593

NCT06427239

NCT07232875

NCT07503639

NCT06773130

NCT06547736

NCT07131514

NCT06770452

NCT06620848

Known as HRS-4642 Injection HRS-4642 Injection: 500 mg intravenous infusion on Day 1, and 1200 mg intravenous infusion on Day 8, every 3 weeks per cycle.” NCT07240766
Action Inhibit “HRS-4642 is a new, high‑affinity, noncovalent KRAS-G12D inhibitor.” PMID 42426224 Jul 2026
Route Intravenous “Formulated as a liposomal nanoparticle for intravenous administration” PMID 42426224 Jul 2026
Target KRAS “HRS-4642 is a new, high‑affinity, noncovalent KRAS-G12D inhibitor.” PMID 42426224 Jul 2026